Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-986178 + SD-101 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986178 | BMS986178|BMS 986178 | OX40 Antibody 14 | BMS-986178 is an activating monoclonal antibody to TNFRSF4 (OX40, CD134), which mimics the binding of the ligand, TNFSF4 (OX40L, CD252), to stimulate proliferation of T-cells and enhance an anti-tumor response (PMID: 33148673). | |
SD-101 | SD101|SD 101 | TLR9 Agonist 9 | SD-101 is an oligonucleotide which interacts with Toll-Like Receptor 9 (TLR9) and activates memory T helper cells 1 (Th1) (PMID: 30154193, PMID: 31921384). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03410901 | Phase I | BMS-986178 + SD-101 | TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas | Active, not recruiting | USA | 0 |
NCT03831295 | Phase I | BMS-986178 + SD-101 | SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies | Completed | USA | 0 |